![](https://images.squarespace-cdn.com/content/v1/6643af61e01ef50807274897/28c19d4f-9635-459c-b882-5eb618974dc3/4218-A+CK-Pan%28FITC%29+Foxp3%28CY3%29+CD4%28CY5%29_10.2x.tif+%28RGB%29.jpg)
PUBLICATIONS
2024
Wu MJ, Kondo H, Kammula AV, Shi L, Xiao Y, Dhiab S, Xu Q, Slater C, Avila OI, Merritt J, Kato H, Kattel P, Sussman J, Gritti I, Eccleston J, Sun Y, Cho H, Olander K, Katsuda T, Shi DD, Savani MR, Smith BC, Cleary J, Mostoslavsky R, Vijay V, Kitagawa Y, Wakimoto H, Jenkins R, Yates K, Paik J, Tassinari A, Saatcioglu DH, Tron A, Hass W, Cahill D, McBrayer SK, Manguso R, Bardeesy N. Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity. Science. 2024; 385: eadl6173. DOI:10.1126/science.adl6173
Zhang Y, Wu MJ, Li YC, Lu WC, Chang CJ, Yang JY. Metabolic switch regulates lineage plasticity and induces synthetic lethality in triple-negative breast cancer. Cell Metabolism (2024). https://doi.org/10.1016/j.cmet.2023.12.003
2023
Ebrahimi-Nik H, Iracheta-Vellve A, Hamel K, Olander K, Davis T, McGuire K, Halvorsen G, Avila O, Patel C, Kim S, Kammula A, Muscato A, Halliwill K, Geda P, Klinge K, Xiong Z, Duggan R, Mu L, Yeary M, Patti J, Balon T, Mathew R, Backus C, Kennedy D, Chen A, Longenecker K, Klahn J, Hrusch C, Krishnan N, Hutchins C, Aguado J, Bulic M, Tiwari P, Colvin K, Chuong C, Kohnle I, Rees M, Boghossian A, Ronan M, Roth J, Wu MJ, Cheruiyot C, Sen D, Griffin G, Golub T, Bardeesy N, Decker J, Yang Y, Guffroy M, Fossey S, Trusk P, Sun I, Liu Y, Qiu W, Sun Q, Paddock M, Farney E, Beauregard C, Frost J, Yates K, Kym P, Manguso R. PTPN2/N1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity. Nature (2023). https://doi.org/10.1038/s41586-023-06575-7
Shi L, Shen W, Davis M, Kong K, Vu Phuong, Saha S, Adil R, Kreuzer J, Egan R, Lee T, Greninger P, Shrimp J, Zhao W, Wei T, Zhou M, Eccleston J, Sussman J, Manocha U, Weerasekara V, Kondo H, Vijay V, Wu MJ, Kearney S, Ho J, McClanaghan J, Murchie E, Crowther G, Patnaik S, Boxer M, Shen M, Ting D, Kim W, Stanger B, Deshpande V, Ferrone C, Benes C, Haas W, Hall M, Bardeesy N. SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers. Nature Cancer (2023), https://doi.org/10.1038/s43018-023-00523-0. PMID: 36914816.
Cable J, Rathmell JC, Pearce EL., Ho PC, Haigis, MC, Mamedov MR., Wu MJ, Kaech SM, Lynch L, Febbraio MA, Bapat SP, Hong HS, Zou W, Belkaid Y, Sullivan ZA, Keller A, Wculek SK, Green DR, Postic C, Amit I, Benitah SA, Jones RG, Reina-Campos M, Torres SV, Beyaz S, Brennan D, O’Neill LAJ, Perry RJ, Brenner, D. (2023). Immunometabolism at the crossroads of obesity and cancer—a Keystone Symposia report. Ann NY Acad Sci., 00, 1– 13. https://doi.org/10.1111/nyas.14976
2022
Wu MJ, Shi L, Merritt J, Zhu A, Bardeesy N. Biology of IDH Mutant Cholangiocarcinoma. Hepatology. 2022; 75: 1322– 1337. doi: 10.1002/hep.32424
Berchuck J, Facchinetti F, DiToro D, Baiev I, Majeed U, Reyes S, Shroff R, Chen C, Zhang K, Sharman R, Uson Junior P, Maurer J, Shroff R, Pritchard C, Wu MJ, Catenacci D, Javle M, Friboulet L, Hollebecque A, Bardeesy N, Zhu A, Lennerz J, Tan B, Board M, Parikh A, Kiedrowski L, Kelley M, Juric D, Goyal L. The Clinical Landscape of Cell-Free DNA Alterations in 1,671 Patients with Advanced Biliary Tract Cancer. Annals of Oncology (2022), doi: https://doi.org/10.1016/j.annonc.2022.09.150.
Wu Q, Zhen Y, Shi L, Vu P, Greninger P, Adil R, Merritt J, Egan R, Wu MJ, Ferrone C, Deshpande V, Gordan J, Juric D, Goyal L, Benes CH, Bardeesy N. EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion-positive cholangiocarcinoma. Cancer Discovery. 2022 May 2; 12 (5): 1378–1395. doi: 10.1158/2159-8290.CD-21-1168
Wu MJ, Shi L, Dubrot J, Merritt J, Vijay V, Wei TY, Kessler E, Olander K, Adil R, Pankaj A, Tummala KS, Weeresekara V, Zhen Y, Wu Q, Luo M, Shen W, García-Beccaria M, Fernández-Vaquero M, Hudson M, Ronseaux S, Sun Y, Saad-Berreta R, Jenkins RW, Wang T, Heikenwälder M, Ferrone C, Goyal L, Nicolay B, Deshpande V, Kohli RM, Zheng H, Manguso RT, Bardeesy N. Mutant-IDH inhibits IFNγ-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma. Cancer Discovery. 2022 March 8; 12 (3): 812–835. doi: 10.1158/2159-8290.CD-21-1077. (Cover story featured in issue)
2020
Kim MR*, Wu MJ*, Zhang Y, Yang JY, Chang CJ. TET2 directs mammary luminal cell differentiation and endocrine response. Nature communication. 2020 Sep 15;11(1):4642. doi: 10.1038/s41467-020-18129-w. (*denotes co-first authors)
2019
Wu MJ, Chen YS, Kim MR, Chang CC, Gampala S, Zhang Y, Wang Y, Yang JY, Chang CJ. Epithelial-mesenchymal transition directs stem cell polarity via regulation of mitofusin. Cell Metabolism. 2019 Apr 2; 29 (4), 993-1002. doi: 10.1016/j.cmet.2018.11.004.
2010-2017
Wu MJ, Kim MR, Chen YS, Yang JY, Chang CJ. Retinoic Acid Directs Breast Cancer Cell State Changes through Regulation of TET2-PKCζ Pathway. Oncogene. 2017 Jun 1; 36(22): 3193-3206. doi: 10.1038/onc.2016.467.
Wu MJ, Chang CJ. High Fat Diet-induced Breast Cancer Model in Rat. Bio-protocol. 2016 Jul 5; 6(13): e1852. doi: 10.21769/BioProtoc.1852.
Wu MJ, Kim MR, Chang CJ. Regulation of microRNA-200c in cancer stem cells. Oncoscience. 2015 Aug 20; 2(9): 745-746. doi: 10.18632/oncoscience.204.
Chang CC*, Wu MJ*, Yang JY, Camarillo I, Chang CJ. Leptin-STAT3-G9a signaling promotes obesity-mediated breast cancer progression. Cancer Research. 2015 Jun 1; 75(11): 2375–2386. doi: 10.1158/0008-5472.CAN-14-3076. (*denotes co-first authors)
Chao CH, Chang CC, Wu MJ, Ko HW, Wang D, Hung MC, Yang JY, Chang CJ. Leptin-STAT3-G9a signaling promotes obesity-mediated breast cancer progression. J Clin Invest. 2014;124(7):3093–3106. doi.org/10.1172/JCI73351.
Chang CW*, Chen CC*, Wu MJ*, Chen YS, Chen CC, Sheu SJ, Lin TW, Chou SH, Lin SC, Liu CJ, Lee TC, Huang CY, Lo JF. Active component of Antrodia cinnamomea Mycelia Targeting Head and Neck Cancer Initiating Cells through Exaggerated Autophagic Cell Death. Evidence-Based Complementary and Alternative Medicine. 2013 Jun 12; 2013: 946451. doi:10.1155/2013/946451. (*denotes co-first authors)
Chen YS, Wu MJ, Huang CY, Lin SC, Chuang TH, Yu CC, & Lo JF. CD133/Src Axis Mediates Tumor Initiating Property and Epithelial-Mesenchymal Transition of Head and Neck Cancer. PLoS ONE. 2011 Nov 28; 6(11): e28053. doi: 10.1371/journal.pone.0028053.
Wu MJ, Jan CI, Yu YH, Huang CY, Lin SC, Chen YS, Tsay YG, Lo JF, and Yu CC (2010). Elimination of head and neck cancer initiating cells through targeting glucose regulated protein78 signaling. Mol Cancer. 2010 Oct 27; 9:283. doi: 10.1186/1476-4598-9-283.